Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population

Respirology

Volumn 20, Issue 8, 2015, Pages 1222-1228

  Lee, Sang Haak ^a   Lee, Jongmin ^a   Yoo, Kwang Ha ^b   Uh, Soo Taek ^c   Park, Myung Jae ^d   Lee, Sang Yeub ^e   Kim, Jae Yeol ^f   Kim, Deog Kyeom ^g   Kim, Seung Joon ^h   Lee, Kwan Ho ⁱ   Yoo, Chul Gyu ^j  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Chung Ang University College of Medicine   (South Korea)

^g Seoul National University Boramae Hospital   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Yeungnam University College of Medicine   (South Korea)

^j Seoul National University College of Medicine   (South Korea)

more..

Author keywords

aclidinium bromide; cholinergic antagonist; chronic obstructive pulmonary disease; safety; treatment outcome

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER INHALER; DYSPNEA; DYSURIA; ECG ABNORMALITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEALTH STATUS; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPRAIN; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; T WAVE; THIRST; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; THERAPEUTIC USE;

AGED; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TROPANES;

EID: 84945455873     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12641     Document Type: Article

References (19)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S,. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397-412.
2. Lindberg A, Bjerg A, Ronmark E, Larsson LG, Lundback B,. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir. Med. 2006; 100: 264-272.
3. Coulson FR, Fryer AD,. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003; 98: 59-69.
4. Beeh KM, Welte T, Buhl R,. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002; 69: 372-379.
5. Sentellas S, Ramos I, Alberti J, Salva M, Anton F, Miralpeix M, Beleta J, Gavalda A,. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur. J. Pharm. Sci. 2010; 39: 283-290.
6. Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, Caracta CF, Garcia Gil E,. Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012; 141: 745-752.
7. Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E,. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm. Pharmacol. Ther. 2012; 25: 248-253.
8. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF,. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9: 90-101.
9. Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF,. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin. Drug Investig. 2013; 33: 893-904.
10. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E,. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830-836.
11. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et-al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
12. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr,. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
13. Gross NJ,. Tiotropium bromide. Chest 2004; 126: 1946-1953.
14. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ,. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
15. Wedzicha JA, Donaldson G, Chuecos F, Garcia Gil E,. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: pooled analysis of phase III studies. Eur. Respir. J. 2014; 44: A1888.
16. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M,. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J. Clin. Pharmacol. 2009; 49: 1239-1246.
17. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P,. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int. J. Clin. Pharmacol. Ther. 2009; 47: 460-468.
18. Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S,. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm. Pharmacol. Ther. 2012; 25: 193-199.
19. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian CSI. Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012; 17: 379-389.